Awareness of the development of age-related macular degeneration (AMD) has been increasing slowly with the recognition of the advancing age of the population.
This article was reviewed by Paulo E. Stanga, MD
When considering accomplishments recorded in the arena of gene therapy, the “firsts” are impressive.
Given the high incidence of age-related macular degeneration (AMD)—with some 10 to 11 million patients affected, 2 million of which have severe visual loss—the need for treatments to restore vision is clear.
The various multifocal choroidopathies differ in course, prognosis, and treatment. While the prognoses do differ, they are hopeful with early treatment in most cases.
This article was reviewed by Nader Pouratian, MD, PhD
This article was reviewed by Arshad M. Khanani, MD, MA, and Joshua Mali, MD
This article was reviewed by Christopher Rapuano, MD
This article was reviewed by Gairik Kundu, MBBS, MS
This article was reviewed by Jeffrey S. Heier, MD